DK2056871T3 - Proteinmatrixvacciner og fremgangsmåder til fremstilling og administration af sådanne vacciner - Google Patents

Proteinmatrixvacciner og fremgangsmåder til fremstilling og administration af sådanne vacciner Download PDF

Info

Publication number
DK2056871T3
DK2056871T3 DK07836580.6T DK07836580T DK2056871T3 DK 2056871 T3 DK2056871 T3 DK 2056871T3 DK 07836580 T DK07836580 T DK 07836580T DK 2056871 T3 DK2056871 T3 DK 2056871T3
Authority
DK
Denmark
Prior art keywords
protein
antigen
carrier protein
polysaccharide
vaccines
Prior art date
Application number
DK07836580.6T
Other languages
English (en)
Inventor
John J Mekalanos
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of DK2056871T3 publication Critical patent/DK2056871T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (12)

1. Fremgangsmåde til fremstilling af en vaccinesammensætning, som omfatter et antigen, der er indesluttet i bærerproteinmatrixen og er ikke-kovalent forbundet med proteinmatrixen, hvilken fremgangsmåde omfatter (i) blanding af et antigen af interesse valgt fra gruppen bestående af et polysaccharid, en polyalkohol, hvor polyalkoholen er en hydrogeneret form af et carbohydrat, hvor en carbonylgruppe er blevet reduceret til en primær eller sekundær hydroxygruppe, og en polyaminosyrehomopolymer med et bærerprotein, og (ii) tilsætning af en linker, som tværbinder bærerproteinet via sulfhydryl-, amino- eller carboxygrupper på bærerproteinmolekylerne, og (iii) tværbinding af bærerproteinet for at danne en bærerproteinmatrix.
2. Fremgangsmåde ifølge krav 1, hvor vaccinesammensætningen endvidere omfatter en farmaceutisk acceptabel excipiens.
3. Fremgangsmåde ifølge krav 1, hvor det molære forhold mellem antigenet og bærerproteinet er på mellem 1 til 10 og 10 til 1 i vaccinesammensætningen.
4. Fremgangsmåde ifølge krav 1, hvor bærerproteinet er en multimer, navnlig hvor multimeren omfatter mindst 5 subunits, eller hvor multimeren er en homomultimer.
5. Fremgangsmåde ifølge krav 1, hvor fremgangsmåden omfatter reduktion af en Schiff-base i bærerproteinet.
6. Fremgangsmåde ifølge krav 1, hvor bærerproteinet er kovalent tværbundet til mindst ét andet bærerprotein, navnlig hvor den kovalente tværbinding omfatter en peptidbinding mellem en primær aminogruppe i en lysinsidekæde og en carboxygruppe i en aspartat- eller glutamatsidekæde, eller hvor den kovalente binding omfatter en bifunktionel tværbinder, især hvor den bifunktionelle tværbinder er glutaraldehyd, bis[sulfosuccinimidyl]suberat eller dimethyladipimidat.
7. Fremgangsmåde ifølge krav 1, hvor linkeren er en forbindelse med formlen CHO r!-cho, hvor Rn er en lineær eller forgrenet alkylgruppe med 1 til 12 carbonatomer, en lineær eller forgrenet heteroalkylgruppe med 1 til 12 atomer, en lineær eller forgrenet alkengruppe med 2 til 12 carbonatomer, en lineær eller forgrenet alkyngruppe med 2 til 12 carbonatomer, en aromatisk rest med 5 til 10 carbonatomer, et cyklisk system med 3 til 10 atomer, (CH2CH2O) qCfhCER-, hvor q er 1 til 4, eller hvor linkeren er glutaraldehyd, m-maleimidobenzoyl-N-hydroxysuccinimidester, carbodiimid eller bis-diazoteret benzidin.
8. Fremgangsmåde ifølge krav 1, hvor bærerproteinet er difteritoksin eller en mutant deraf, difteritoksoid, tetanustoksin eller en mutant deraf, tetanustoksoid, Pseudomonas aeruginosa-eksotoksin A eller en mutant deraf, koleratoksin B-subunit, tetanustoksinfragment C, bakterielt flagellin, pneumolysin, listeriolysin O, et ydermembranprotein fra Neisseria meningitidis, Pseudomonas aeruginosa-Hcpl-protein, varmelabilt Escherichia coli-enterotoksin, shigalignende toksin, humant LTB-protein, en proteinekstrakt fra hele bakterieceller, den dominant negative mutant (DNI) af det beskyttende antigen fra Bacillus anthracis eller Escherichia coli-beta-galactosidase, navnlig hvor de hele bakterieceller er Pseudomonas aeruginosa- eller Streptococcus-celler, eller hvor det bakterielle flagellin er Vibrio cholerae-flagellinproteinet.
9. Fremgangsmåde ifølge krav 1, hvor det shigalignende toksin er Shigella-SltB2-proteinet.
10. Fremgangsmåde ifølge krav 1, hvor polysaccharidet omfatter mindst 18 rester, eller hvor polysaccharidet er et Streptococcus pneumoniae-polysaccharid, Francisella tularensis-polysaccharid, Bacillus anthracis-polysaccharid, Haemophilus influenzae-polysaccharid, Salmonella typhi-polysaccharid, Shigella-art-polysaccharider, Salmonella-art-polysaccharider eller Neisseria meningitidis-polysaccharid, især hvor Streptococcus pneumoniae-polysaccharidet er kapseltype 3, 4, 6B, 7A, 7B, 7C, 7F, 9A, 9L, 9N, 9V, 12A, 12B, 12F, 14, 15A, 15B, 15C, 15F, 17, 18B, 18C, 19F, 23F, 25A, 25F, 33F, 35, 37, 38, 44 eller 46, eller hvor Francisella tularensis-polysaccharidet er O-antigen.
11. Fremgangsmåde ifølge krav 1, hvor polyaminosyrehomopolymeren er en mikrobiel kapselpolymer, navnlig hvor den mikrobielle kapselpolymer er poly-gamma-D-glutaminsyre fra Bacillus anthracis.
12. Fremgangsmåde ifølge krav 1, som endvidere omfatter et andet antigen af interesse, og hvor fremgangsmåden navnlig endvidere omfatter et tredje antigen af interesse.
DK07836580.6T 2006-08-07 2007-08-07 Proteinmatrixvacciner og fremgangsmåder til fremstilling og administration af sådanne vacciner DK2056871T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83594406P 2006-08-07 2006-08-07
US93376407P 2007-06-08 2007-06-08
PCT/US2007/017528 WO2008021076A2 (en) 2006-08-07 2007-08-07 Protein matrix vaccines and methods of making and administering such vaccines

Publications (1)

Publication Number Publication Date
DK2056871T3 true DK2056871T3 (da) 2018-02-26

Family

ID=39082551

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07836580.6T DK2056871T3 (da) 2006-08-07 2007-08-07 Proteinmatrixvacciner og fremgangsmåder til fremstilling og administration af sådanne vacciner

Country Status (12)

Country Link
US (3) US8642042B2 (da)
EP (2) EP2056871B1 (da)
JP (2) JP5745221B2 (da)
KR (1) KR101446238B1 (da)
AU (1) AU2007284878B2 (da)
BR (1) BRPI0715396B8 (da)
CA (1) CA2660022C (da)
DK (1) DK2056871T3 (da)
ES (1) ES2658851T3 (da)
MX (1) MX2009001412A (da)
TW (1) TWI565713B (da)
WO (1) WO2008021076A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007284878B2 (en) 2006-08-07 2013-01-17 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
US8524394B2 (en) * 2007-11-22 2013-09-03 Samsung Sdi Co., Ltd. Negative electrode and negative active material for rechargeable lithium battery, and rechargeable lithium battery including same
WO2010027473A2 (en) 2008-09-03 2010-03-11 Board Of Trustees Of Michigan State University Immunogenic escherichia coli heat stable enterotoxin
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
KR20120104178A (ko) * 2009-09-09 2012-09-20 메트리박스 리써치 앤 디벨롭먼트 코포레이션 면역원성이 개선된 단백질 매트릭스 백신
US20110135689A1 (en) * 2009-11-30 2011-06-09 University Of Iowa Research Foundation Vaccine, therapeutic composition and methods for treating or inhibiting francisella tularenis
SG181750A1 (en) 2009-12-17 2012-07-30 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
NZ602971A (en) 2010-04-23 2014-11-28 Serum Inst India Ltd Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
WO2012023008A2 (en) * 2010-05-03 2012-02-23 Dcb-Usa Llc Polysaccharide conjugation with detoxified e. coli heat labile enterotoxin (lt) used as vaccine
US9724401B2 (en) 2011-05-18 2017-08-08 Matrivax, Inc. Protein matrix vaccine compositions including polycations
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
WO2014111724A1 (en) 2013-01-18 2014-07-24 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
EP2970908B1 (en) 2013-03-15 2019-12-25 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2015073831A1 (en) * 2013-11-15 2015-05-21 Liquidia Technologies, Inc. Virtual conjugate particles
KR102049826B1 (ko) * 2014-01-21 2019-12-03 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
EP3145953A1 (en) * 2014-05-21 2017-03-29 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2018009906A1 (en) * 2016-07-08 2018-01-11 President And Fellows Of Harvard College Whole cell-protein conjugates and methods of making the same
CN109890413B (zh) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018227177A1 (en) * 2017-06-10 2018-12-13 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3079111A1 (en) 2017-10-13 2019-04-18 The Research Foundation For The State University Of New York Comprehensive vaccine design for commensal disease progression
CN111683678B (zh) 2017-12-06 2024-01-26 默沙东有限责任公司 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
WO2020121159A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
TWI788610B (zh) 2018-12-19 2023-01-01 美商默沙東有限責任公司 包含肺炎鏈球菌多醣-蛋白質結合物之組合物及其使用方法
CN114129719A (zh) * 2021-12-03 2022-03-04 张公义 广谱疫苗的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4761470A (en) * 1985-12-16 1988-08-02 Merck & Co., Inc. Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1992017436A1 (en) 1991-03-28 1992-10-15 Holmes, Michael, John Cross-linking agent
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CN1211192A (zh) * 1995-09-18 1999-03-17 美国陆军医疗材料研究指挥部 生产非共价复合的多价蛋白体亚基疫苗的改进方法
US6821331B2 (en) * 2003-04-09 2004-11-23 Wisconsin Alumni Research Foundation Protein-polysaccharide hybrid hydrogels
EP1522585A1 (en) * 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines
AU2007284878B2 (en) * 2006-08-07 2013-01-17 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines

Also Published As

Publication number Publication date
EP2056871A2 (en) 2009-05-13
MX2009001412A (es) 2009-04-24
BRPI0715396B8 (pt) 2021-05-25
US9216223B2 (en) 2015-12-22
US20080095803A1 (en) 2008-04-24
BRPI0715396B1 (pt) 2019-02-19
US20160136257A1 (en) 2016-05-19
KR20090066272A (ko) 2009-06-23
JP2014058530A (ja) 2014-04-03
ES2658851T3 (es) 2018-03-12
KR101446238B1 (ko) 2014-10-01
TWI565713B (zh) 2017-01-11
US8642042B2 (en) 2014-02-04
CA2660022A1 (en) 2008-02-21
CA2660022C (en) 2014-11-04
US9533032B2 (en) 2017-01-03
WO2008021076A3 (en) 2008-12-04
EP2056871B1 (en) 2017-11-15
EP2056871A4 (en) 2010-04-14
AU2007284878A1 (en) 2008-02-21
EP3260134A1 (en) 2017-12-27
BRPI0715396A2 (pt) 2013-11-26
WO2008021076A2 (en) 2008-02-21
JP2010500354A (ja) 2010-01-07
AU2007284878B2 (en) 2013-01-17
JP5745221B2 (ja) 2015-07-08
TW200823230A (en) 2008-06-01
US20140186399A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
US9533032B2 (en) Protein matrix vaccines and related methods of making and administering such vaccines
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
EP2709656B1 (en) Protein matrix vaccine compositions including polycations
CN101553246A (zh) 蛋白质基质疫苗及这种疫苗的制备和给药方法